The addition of radiation to chemotherapy did not improve overall survival in patients with locally advanced endometrial cancer, a recent phase 3 trial found.

A coroner found there were "missed opportunities" to treat a 38-year-old woman with cancer. Carla Smith, 38, who died on 7 ...

The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, ...

Overweight and obesity were associated with improved survival after treatment of endometrial cancer with immunotherapy, especially in high-risk subtypes, when compared to patients with a normal BMI.

Acrivon Therapeutics said the Food and Drug Administration has granted Breakthrough Device designation for its ACR-368 OncoSignature assay, an immunofluorescence assay for the identification of ...

The surgical management of endometrial cancer has been markedly changed by minimally invasive techniques. After three decades of laparoscopy, robotic surgery has built upon and expanded the ...

GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in the RUBY trial.

Uterine manipulation with an intrauterine device is the surgical method used for early-stage cervical cancer. In this study, ...

"The lack of a significant link between AmygA and LN metastasis in premenopausal women suggests that menopausal status may ...